Bausch Health Companies Inc.
6.44USD
-0.0500 (-0.77%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on BHC.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 8.1B | 8.8B | 9.6B | 10.3B | 10.9B | 10.9B |
| Q1 | 1.9B | 1.9B | 2.2B | 2.3B | 2.5B | — |
| Q2 | 2.0B | 2.2B | 2.4B | 2.5B | 2.9B | — |
| Q3 | 2.0B | 2.2B | 2.5B | 2.7B | 2.8B | — |
| Q4 | 2.2B* | 2.4B* | 2.6B* | 2.8B* | 2.8B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -.620 | -1.62 | -.130 | .420 | 4.52 | 4.29 |
| Q1 | -.190 | -.550 | -.170 | -.160 | -3.82 | — |
| Q2 | -.400 | .070 | .030 | .400 | .680 | — |
| Q3 | 1.10 | -1.03 | -.230 | .480 | 1.24 | — |
| Q4 | -1.13* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -.107* |
| .253* |
| -.299* |
| 1.29 |
| — |
Debt level and coverage